Pregled bibliografske jedinice broj: 1206526
Arterial hypertension following COVID-19
Arterial hypertension following COVID-19 // Journal of Hypertension 40(Suppl 1)
Atena, Grčka, 2022. str. e178-e178 doi:10.1097/01.hjh.0000837212.76868.3f (poster, recenziran, sažetak, znanstveni)
CROSBI ID: 1206526 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Arterial hypertension following COVID-19
Autori
Delalić, Diđi ; Jug, Juraj ; Varahabhatla, Vamsi ; Prkačin, Ingrid
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Journal of Hypertension 40(Suppl 1)
/ - , 2022, E178-e178
Skup
The ESH 2022 Annual Meeting
Mjesto i datum
Atena, Grčka, 17.06.2022. - 20.06.2022
Vrsta sudjelovanja
Poster
Vrsta recenzije
Recenziran
Ključne riječi
Arterial Hypertension ; COVID-19 ; Post-COVID
Sažetak
The aim of this study was to determine the frequency of newly verified or worsened existing hypertension in patients who had COVID-19. In this case-control study which lasted from May 2021 to December 2021, 108 patients (49 males, 59 females) who have had COVID-19 were analyzed at the Emergency department in Clinical Hospital Merkur, a tertiary care center in Zagreb, Croatia. In order to be categorized as a COVID patient, a positive PCR test at a single point in time was required. According to the accepted definitions of COVID-19 and its manifestations in respect to time from a positive PCR test, the patients were divided into two groups: acute COVID patients (PCR test positive < 30 days ago) and post- acute COVID patients (PCR test positive > 30 days ago). Additionally, the post-acute group was subdivided into the following groups: sub-acute (30– 90 days from positive PCR test), chronic (90–180 days from positive PCR test), and “long COVID” (>180 days from positive PCR test). Patients’ age, history, BMI, laboratory values, and antihypertensive therapy were recorded. Out of 108 patients studied, 13 (12.04 %) had either newly verified (8) or worsened existing (5) arterial hypertension. Among those, the median time from a verified SARS-CoV-2 infection to onset of symptoms was 90 days. When divided into groups, 5 were in the acute, 3 in the sub-acute, 4 in the chronic, and 1 in the “long COVID” group. Compared to the rest of the study population, patients presenting with arterial hypertension had significantly higher systolic (median 155 vs. 126 mmHg, p = 0.004) and diastolic (median 90 vs 80 mmHg, p = 0.02) blood pressure and were non-significantly younger (median 48 vs 58 years, p = 0.067). Arterial hypertension following COVID-19, either newly verified or worsened existing, is a relatively common (12.04% of our patient pool) occurrence and more effort should be directed into evaluating patients’ blood pressure values following COVID-19 in order to make a timely diagnosis and start proper treatment early.
Izvorni jezik
Engleski
Znanstvena područja
Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)
POVEZANOST RADA
Ustanove:
Klinička bolnica "Merkur",
Medicinski fakultet, Zagreb
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE